STOCK TITAN

CV insider: Wen-Herng Henry receives 2,887 RSUs on 09/15/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CapsoVision, Inc. (CV) director Wen-Herng Henry received a grant of 2,887 Restricted Stock Units (RSUs) on 09/15/2025. Each RSU represents a contingent right to one share of the company's common stock and the RSUs are scheduled to vest on 12/31/2025. The reported grant carries a $0 price per unit and, after the grant, Mr. Henry beneficially owns 2,887 shares attributable to these RSUs on a direct basis. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/17/2025.

Positive

  • Director alignment: Granting RSUs aligns the director's interests with shareholders by tying compensation to company equity.
  • Clear vesting schedule: RSUs have a specific vesting date of 12/31/2025, providing transparent timelines for potential share issuance.

Negative

  • No material negative events disclosed: The filing does not report disposals, exercises, or material transactions adverse to shareholders.
  • Limited detail on terms: The Form 4 does not disclose any performance conditions, transfer restrictions, or potential dilution magnitude beyond the RSU count.

Insights

TL;DR: A routine director RSU grant for 2,887 shares vesting at year-end; immaterial to company valuation absent further context.

This Form 4 discloses a non-cash equity compensation award to a director: 2,887 RSUs granted on 09/15/2025 that vest on 12/31/2025 and convert one-for-one into common shares. The grant price is listed as $0, reflecting a standard stock-unit award rather than a purchase. The filing reports direct beneficial ownership of 2,887 shares post-grant. As reported, there are no disposals, exercises, or derivative instruments beyond the RSUs, and no additional terms such as performance conditions are disclosed in the filing.

TL;DR: Standard director RSU grant disclosed; typical governance practice to align director incentives with shareholders.

The disclosure is concise and follows Section 16 reporting requirements. The RSUs vest on a specified future date (12/31/2025) and are recorded as direct beneficial ownership. The filing is signed by an attorney-in-fact and provides the minimal contract terms: one RSU equals one share and vesting date. No indications of accelerated vesting, clawbacks, or unusual transfer restrictions are present in this document.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
King Wen-Herng Henry

(Last) (First) (Middle)
C/O CAPSOVISION, INC.
18805 COX AVENUE, SUITE 250

(Street)
SARATOGA CA 95070

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (RSU) (1) 09/15/2025 A 2,887 (2) (2) Common Stock 2,887 $0 2,887 D
Explanation of Responses:
1. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. These RSUs are scheduled to vest on December 31, 2025
Remarks:
/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Wen-Herng Henry King 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CapsoVision (CV) disclose in this Form 4?

The Form 4 reports that director Wen-Herng Henry was granted 2,887 RSUs on 09/15/2025, vesting on 12/31/2025, with a reported price of $0.

How many shares will Wen-Herng Henry own after the reported transaction?

The filing reports beneficial ownership of 2,887 shares attributable to the RSUs on a direct basis following the grant.

When do the RSUs granted to the director vest?

The RSUs are scheduled to vest on 12/31/2025 as stated in the filing.

What is the economic cost reported for the RSU grant?

The filing lists a $0 price per RSU, indicating a non-cash grant of restricted stock units.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by an attorney-in-fact for Wen-Herng Henry on 09/17/2025.
CapsoVision, Inc.

NASDAQ:CV

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

283.40M
27.71M
40.69%
0.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA